BAT1706 vs bevacizumab-awwb

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

BAT1706 · Avzivi

Marketed by Bio-Thera Solutions and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03329911 · Phase 3 · completed

This double-blind, randomized Phase 3 trial compared BAT1706, a proposed bevacizumab biosimilar, with EU-sourced Avastin, each with paclitaxel and carboplatin, in 651 patients with advanced non-squamous non-small cell lung cancer. The primary endpoint was overall response rate at week 18, tested for equivalence against pre-specified margins (risk ratio 0.75 to 1.33 or 0.73 to 1.36; risk difference -0.12 to 0.15). Both the risk ratio (1.08, 90% CI 0.94 to 1.24) and the risk difference (0.03, 95% CI -0.04 to 0.11) fell inside the margins, so the equivalence primary was met. Source: the peer-reviewed paper (Cancer Med 2023).

Reported efficacy

Overall Response Rate (Week 18): Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023). (met)

Result source: NCT03329911

bevacizumab-awwb · MVASI

Marketed by Amgen and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT01966003 · Phase 3 · completed

This randomized, quadruple-blind, active-controlled Phase 3 trial in 642 patients with advanced non-small cell lung cancer compared the biosimilar bevacizumab-awwb with reference bevacizumab, both added to chemotherapy. Objective response rates were closely matched (39.0% vs 41.7%), and the prespecified statistical test showed the two products were clinically equivalent.

Reported efficacy

Percentage of Participants With an Objective Response (Disease assessments were performed at weeks 1, 7, 13, 19, and approximately every 9 weeks thereafter. The mean actual follow-up time from randomization was 4.7 and 5.0 months for ABP 215 and bevacizumab, respectively.): Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results). (met)

Result source: NCT01966003

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBAT1706bevacizumab-awwb
PFS, median—Not posted · NCT033299116.6 vs 7.9vs Bevacizumabn 328NCT01966003
OS, median—Not posted · NCT03329911—Not reported
ORR—Not posted · NCT0332991139% vs 41.7%vs Bevacizumabn 328NCT01966003
Duration of response, median—Not posted · NCT033299115.8 vs 5.6vs Bevacizumabn 128NCT01966003

PFS, median

BAT1706
—Not posted · NCT03329911
bevacizumab-awwb
6.6 vs 7.9vs Bevacizumabn 328NCT01966003

OS, median

BAT1706
—Not posted · NCT03329911
bevacizumab-awwb
—Not reported

ORR

BAT1706
—Not posted · NCT03329911
bevacizumab-awwb
39% vs 41.7%vs Bevacizumabn 328NCT01966003

Duration of response, median

BAT1706
—Not posted · NCT03329911
bevacizumab-awwb
5.8 vs 5.6vs Bevacizumabn 128NCT01966003
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. BAT1706: 3 of 4 rows · bevacizumab-awwb: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBAT1706bevacizumab-awwb
Dropout rate
31.7%
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
82.3%
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs
—
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Serious AEs
36.6%
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
26.2%
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs
musculoskeletal and connective tissue disorders 1.5%
renal and urinary disorders 0.9%
hepatobiliarydisorders 0.3%
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
alopecia 43.2%
nausea 25.3%
anaemia 20.1%
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

BAT1706

ORR 44.6% (n=325) vs 47.9% (n=326) EU Avastin® @ 18wk
event count · % of participants
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 · converted to % from 145 Participants as posted

bevacizumab-awwb

ORR 39% (n=328) vs 41.7% (n=314) Bevacizumab
responder rate · % of participants
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Duration of Response 5.8 vs 5.6 Bevacizumab months
time to event · months
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
PFS 6.6 vs 7.9 Bevacizumab months
time to event · months
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Overall Survival NA vs NA Bevacizumab months
time to event · months
NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT1706's landscape · bevacizumab-awwb's landscape